<DOC>
	<DOC>NCT00240565</DOC>
	<brief_summary>This study will further characterize the activity of Tositumomab and Iodine I 131-Tositumomab in patients with relapsed indolent non-Hodgkin's Lymphoma who have progressed following treatment with rituximab.</brief_summary>
	<brief_title>Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non-Hodgkin's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<criteria>Inclusion criteria: Patients must have evidence of persistent or progressive follicular grade, 1, 2 or 3 or marginal zone Bcell nonHodgkin's lymphoma. Must have received at least two prior courses of systemic treatment including at least one treatment of rituximab (lymphoma must not have progressed during their most recent systemic chemotherapy treatment). Must have evidence that their lymphoma expresses CD20 antigen and have adequate renal and hepatic function. Exclusion criteria: Received chemotherapy, radiation therapy, immunosuppressants or cytokine treatment within 4 weeks prior to study entry. Have active obstructive hydronephrosis. Had prior autologous hematopoietic stem cell transplant or any allogenic stem cell transplant. Have active infection requiring IV antibiotics. Have brain or leptomeningeal metastasis. Had previous allergic reaction to iodine, previously received radioimmunotherapy or are currently receiving approved or experimental anticancer drugs. Patients who are pregnant or breast feeding, have known HIV infection, or are Human antimurine antibody (HAMA) positive. Other criteria will be evaluated at the screening visit.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>BEXXAR</keyword>
	<keyword>non-Hodgkin's Lymphoma</keyword>
	<keyword>tositumomab</keyword>
	<keyword>I-131</keyword>
</DOC>